2026-10-14T15:53:52Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33957076 2026-09-21T17:40:13Z category_7 category_21 category_873 category_106 category_132 category_134 portal_5 item_type_3 month_year_09_2026

<p>Detailed protocols for all laboratory measurements.</p> Xunuo Chen (25084377) Mengyun Lei (25084380) Jun Tang (32983) Huawei Wang (805705) Jiawei Chen (186337) Yanxin Liu (102838) Shuting Li (6552) Fang Liu (13271) Yonge Wang (25084383) Zhiqiang Li (102723) Zhe Dai (8552142) Medicine Biotechnology Chemical Sciences not elsewhere classified Science Policy Infectious Diseases Virology subsequent multicenter large serum metabolomic profiles pilot trial aims offer new insight novel therapeutic avenue improve clinical outcomes hour postprandial glucose fasting plasma glucose continuous glucose monitoring 6 consecutive days gut microbiota plays gut microbiota composition suboptimal glycemic outcomes standard insulin therapy related metabolites ). chain fatty acids controlled pilot study primary efficacy endpoint 0 &# 8211 xlink "> dysbiosis safety endpoints include 4 weeks post composite achievement rate 12 weeks post oral yfmt capsules xlink "> weeks 4 gut microecosystem insulin optimization glycemic metrics composite target bile acids study may scale study week follow retention rate recruitment rate randomly allocated preliminary efficacy placebo capsules necessary evidence key role infection markers immune responses glycated hemoglobin day run bowel preparation adverse events <p>Detailed protocols for all laboratory measurements.</p> 2026-09-21T17:40:10Z Dataset Dataset 10.1371/journal.pone.0343078.s002 https://figshare.com/articles/dataset/_p_Detailed_protocols_for_all_laboratory_measurements_p_/33957076 CC BY 4.0